Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | RARB | P10826 | 8/20 | 0.75 |
| ▸ | RARG | P13631 | 7/20 | 0.75 |
| ▸ | RARA | P10276 | 5/20 | 0.75 |
| ▸ | RXRB | P28702 | 5/20 | 0.75 |
| ▸ | RXRG | P48443 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.75 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | ESR1 | P03372 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | DRD1 | P21728 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538726 | 0.87 | RXRA (0.77) | RXRARARBRARGRARARXRB | |
| Bexarotene SCHEMBL9025 | 0.86 | RXRA (1.00) | RXRARARBRARGRARARXRB | |
| SCHEMBL1072953 | 0.86 | RXRA (1.00) | RXRARARBRARGRARARXRB | |
| Bexarotene SCHEMBL29412584 | 0.86 | RXRA (1.00) | RXRARARBRARGRARARXRB | |
| Bexarotene SCHEMBL5322954 | 0.86 | RXRA (1.00) | RXRARARBRARGRARARXRB | |
| SCHEMBL6889176 | 0.84 | RXRA (1.00) | RXRARARBRARGRARARXRB | |
| Bexarotene SCHEMBL4432606 | 0.84 | RXRA (0.97) | RXRARARBRARGRARARXRB | |
| SCHEMBL2685363 | 0.84 | RXRA (1.00) | RXRARARBRARGRARARXRB | |
| Bexarotene SCHEMBL28672173 | 0.83 | RXRA (0.94) | RXRARARBRARGRARARXRB | |
| SCHEMBL3176118 | 0.83 | RXRA (1.00) | RXRARARBRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391093-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-08-27 | — | — | US | disclosed |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz (US) | 2017-06-29 | — | — | US | disclosed |
| US-9573906-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. | 2016-09-15 | — | — | US | disclosed |
| EP-2910549-A1 | 1,2,3,4-TETRAHYDRO-1,1,4,4-TETRAMETHYLNAPHTHALENE DERIVATIVES USEFUL AS RXR MODULATORS FOR TREATING ALZHEIMER'S DISEASE AND CANCER | Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2015059632-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | ACADIA PHARMACEUTICALS INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents, A body corporate of the State of Arizona, acting for and on | 2014-11-20 | — | — | US | disclosed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| US-6043279-A | COMPOUNDS USED FOR IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0983992-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0983991-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5962731-A | MODIFY LIPID METABOLISM; SKIN DISORDERS,; AUTOIMMUNE DISEASES; FATTY ACID METABOLISM; ANTITUMOR AGENTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0678087-B1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0678087-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| WO-1995004036-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| EP-0637297-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1993021146-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391093-B2 | Therapeutic compounds | PSEN1, PSEN2, MAPT | RXRA 3433/4885RARB 2861/4885RARG 2817/4885 |
| US-20170182046-A1 | THERAPEUTIC COMPOUNDS | PSEN1, PSEN2, MAPT | RXRA 3433/4885RARB 2861/4885RARG 2817/4885 |
| US-20140343079-A1 | THERAPEUTIC COMPOUNDS | MAPT, PSEN1, PSEN2 | RXRA 3109/4885RARB 2411/4885RARG 2187/4885 |
| US-20160263189-A1 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER | NCOR1, NR4A2, NR4A3 | RXRA 4/4885RARB 37/4885RARG 54/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | RXRA 1/4885RARB 6/4885RARG 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.